

References

I-8

1. Approval Letter - MenHibrix. 2012.
2. U.S FDA. FDA Approved Products: Fluarix Quadrivalent. Effective 8/16/13.
3. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 Influenza Season. *Morbidity and Mortality Weekly Report (MMWR)*. 2014;63(32):691-697.
4. Pfizer receives FDA accelerated approval for Trumenba® (meningococcal group b vaccine) for the prevention of invasive meningococcal B disease in adolescents and young adults. *Pfizer*. October 2014.
5. U.S. FDA. October 29, 2014 Approval Letter – Trumenba. October 2014.
6. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines recommendations of the Advisory Committee on Immunization Practices — United States, 2016–17 Influenza Season. *MMWR Morb Mortal Recomm Rep*. 2016;64:1-54.
7. Robinson CL, Romero JR, Kempe A, et al. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger — United States, 2017. *MMWR Morb Mortal Wkly Rep*. 2017;66:134–135. DOI: 15585/mmwr.mm6605e1.
8. Flucelvax® Quadrivalent. [package insert]. Holly Springs, NC. Seqirus Inc; 2017.
9. Heplisav-B™ [package insert]. Berkeley, CA. Dynavax Technologies Corporation; 2017.